Categories AlphaGraphs, Earnings, Technology

Applied Materials Earnings: AMAT Q4 sales rise but miss estimates

Applied Materials, Inc. (NASDAQ: AMAT) this week reported higher earnings and revenues for the fourth quarter of 2021. The top line, however, missed estimates. The semiconductor technology company’s stock traded lower on Friday morning, after closing the previous session higher.

Applied Materials Q4 2021 earnings infographic Fourth-quarter net income, on an adjusted basis, increased to $1.94 per share from $1.25 per share in the prior-year period. Unadjusted profit was $1.71 billion or $1.89 per share, higher than $1.13 billion or $1.23 per share recorded in the fourth quarter of 2020.

The bottom-line growth reflects a 31% increase in net sales to $6.12 billion, which is below the consensus forecast. For the first quarter of 2022, the company expects net sales to be around $6.16 billion, plus or minus $250 million. Adjusted earnings are expected to be between $1.78 per share and $1.92 per share.

“Demand for semiconductors and equipment continues to grow as the pandemic accelerates the digital transformation of the economy, and currently, our supply chain cannot keep up. We expect supply shortages of certain silicon components to persist in the near term, and managing these constraints in partnership with our suppliers and chipmakers is our top priority,” said Gary Dickerson, CEO of Applied Materials.

Read management/analysts’ comments on Applied Materials’ Q4 2021 earnings report

Shares of Applied Materials gained about 66% since the beginning of the year. The stock, which reached a record high this week, traded lower on Friday morning.

Prior Performance

  • <img loading=”lazy” width=”662″ height=”1024″ alt=”” class=”wp-block-jetpack-slideshow_image wp-image-127032″ data-id=”127032″ src=”×1024.jpg” srcset=”×1024.jpg 662w,×300.jpg 194w,×1189.jpg 768w, 827w” sizes=”(max-width: 662px) 100vw, 662px”/>

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Viewing Highlight